Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCND2 | P30279 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244105 | 0.94 | MAPK9 (0.59) | MAPK9HPGDEPHX2PPARGERCC1 | |
| SCHEMBL5241797 | 0.90 | MAPK9 (0.66) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5244896 | 0.90 | MAPK9 (0.79) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5243455 | 0.89 | MAPK9 (0.74) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5242553 | 0.86 | MAPK9 (0.74) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5240189 | 0.86 | MAPK9 (0.65) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5241046 | 0.86 | MAPK9 (0.62) | MAPK9HPGDEPHX2PPARGCRHR1 | |
| SCHEMBL5239995 | 0.86 | MAPK9 (0.80) | MAPK9HPGDEPHX2PPARGCDK4 | |
| SCHEMBL5243122 | 0.86 | MAPK9 (0.67) | MAPK9HPGDEPHX2PPARGJAK2 | |
| SCHEMBL5243430 | 0.84 | MAPK9 (0.62) | MAPK9HPGDEPHX2PPARGJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1539708-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192748-A1 | Heterocyclic compounds | BOEHRINGER INGELHEIM PARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004024699-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192748-A1 | Heterocyclic compounds | IL1B, CCL5, IL4 | MAPK9 1270/4885HPGD 115/4885EPHX2 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.